Immunovia (IMMNOV) Q4 2023 earnings summary

Executive summary

• 2023 priorities shifted to the next-generation pancreatic cancer test after IMMray PanCan-d sales were discontinued; operations were downsized and platforms changed to reduce costs and accelerate development.

• 2024 priorities included finalizing test development, demonstrating clinical value, securing resources and commercial partnerships, with market launch targeted for 2025.

Financial highlights

• Q4 net sales were SEK 155k vs SEK 502k, all from royalties; FY sales were SEK 1,575k vs SEK 1,145k, including SEK 800k test sales and SEK 775k royalties.

• Q4 net loss was SEK 49,020k vs SEK 67,321k and operating loss was SEK 23,406k vs SEK 51,079k; FY net loss was SEK 309,438k vs SEK 168,092k.

• FY 2023 included a SEK 141.7m development-cost write-off; Q4 external and personnel costs fell SEK 24,387k year over year following operational and organizational scaling back.

• Q4 cash burn was SEK 30m vs SEK 53m a year earlier; monthly cash burn was reduced by 50–60% to below SEK 10m.

Outlook and guidance

• Year-end cash was SEK 76.788m and was expected to fund operations under current plans into Q4 2024; additional capital is needed to complete 2024 and fund 2025 operations.

• Model building and initial validation were targeted for Q1/Q2 2024, analytical validity for Q3/Q4 2024 and clinical validity by year-end 2024.

• A non-inferiority comparison with imaging was targeted for 1H 2025; the Leiden CDKN2A clinical-validity study was planned for 1H 2025 and the PRECEDE clinical-utility study for 2025.

• Further studies in 2025 were intended to support reimbursement, with commercial launch targeted for 2025.